RANKL/RANK control Brca1 mutation-driven mammary tumorsVerena Sigl, Josef Penninger, Nnamdi Edokobi et al.|Cell Research|2016Cited by 176
Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast CancerChristian F. Singer, Michael Gnant, Yen Y. Tan et al.|Clinical Cancer Research|2017Cited by 61
Prospective randomized phase II trial to assess the efficacy and safety of neo-adjuvant olaparib/carboplatin (OC) in comparison to docetaxel/epirubicin/cyclophosphamide (TAC) in patients with early triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD): Primary results from the ABCSG 45 trial.Christian F. Singer, Michael Gnant, Dominik Hlauschek et al.|Journal of Clinical Oncology|2025Cited by 3
Temporal Representation Learning of Phenotype Trajectories for pCR Prediction in Breast CancerIvana Janíčková, Georg Langs, Yen Y. Tan et al.|Lecture notes in computer science|2025Cited by 2